Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs

BACKGROUND: Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodgers, Florence, Pepperrell, Toby, Keestra, Sarai, Pilkington, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809643/
https://www.ncbi.nlm.nih.gov/pubmed/33451350
http://dx.doi.org/10.1186/s13063-021-05024-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809643/
https://www.ncbi.nlm.nih.gov/pubmed/33451350
http://dx.doi.org/10.1186/s13063-021-05024-y

Ejemplares similares